ClinicalTrials.gg
CompletedNCT03738397Heads UpUpdated Mar 15, 2024Results posted

A Study to Compare Safety and Efficacy of Upadacitinib to Dupilumab in Adult Participants With Moderate to Severe Atopic Dermatitis

A Phase 3 interventional study of Upadacitinib and Dupilumab in Atopic Dermatitis, sponsored by AbbVie. Completed at 159 sites in 23 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2024-03-15.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
673
Allocation
Randomized
Ages
18 Years to 76 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing upadacitinib in Dermatitis, Atopic — 2 open to participants now, 6 under way, 4 of them phase 3. upadacitinib · Dermatitis, Atopic.

Enrollment
6th of 17
673 · median 272
Started
2019
with 1 other
Phase 3
12 of 17
none open now
Registered
7th of 17
by date
Lead sponsor
15 of 17
AbbVie

Among the 17 studies testing upadacitinib in Dermatitis, Atopic, this one is the 6th largest by enrollment, is one of 2 that started in 2019, is one of 12 in phase 3, and was the 7th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

2 of the 17 studies testing upadacitinib in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About upadacitinib

upadacitinib: first FDA approval 2019 (RINVOQ), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 76 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing upadacitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This study will evaluate upadacitinib compared to dupilumab (Dupixent®) in adults with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.

Read the detailed description

The study is comprised of a 35-day screening period, a 24-week double-blinded treatment period, and a follow-up visit 12 weeks after the last dose. Participants who complete Week 24 have the option to enroll into an open-label study (Study M19-850; NCT04195698) of upadacitinib 30 mg once daily and receive treatment with upadacitinib for an additional 52 weeks.

Participants who meet eligibility criteria will be randomized in a 1:1 ratio to receive either upadacitinib or dupilumab. Randomization will be stratified by Baseline disease severity (Validated Investigator Global Assessment scale for Atopic Dermatitis [vIGA-AD] score of moderate [3] versus severe [4]) and age (\<40, ≥ 40 to \< 65, ≥ 65 years).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Upadacitinib
  • ABT-494
  • Dupilumab
  • Atopic Dermatitis
04

Who can participate

Ages eligible
18 Years to 76 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has active moderate to severe atopic dermatitis (AD) defined by Eczema Area and Severity Index (EASI) ≥ 16, Investigator's Global Assessment (IGA) ≥ 3, ≥ 10% body surface area (BSA) of AD involvement at the Screening and Baseline Visits, and Baseline weekly average of daily Worst Pruritus NRS ≥ 4.
  • Participant is a candidate for systemic therapy or have recently required systemic therapy for AD.

Exclusion criteria

Exclusion Criteria:

  • Participant has prior exposure to Janus Kinase (JAK) inhibitor.
  • Participant has prior exposure to dupilumab.
  • Participant is unable or unwilling to discontinue current AD treatments prior to the study.
  • Participant has requirement of prohibited medications during the study.
  • Participant has other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of AD lesions.
  • Female participant who is pregnant, breastfeeding, or considering pregnancy during the study.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
673 participants (actual)

Study arms

  • Experimental
    Upadacitinib 30 mg QD

    Participants will receive 30 mg upadacitinib orally once a day (QD) up to Week 24 and placebo to dupilumab by subcutaneous injection every other week from Baseline to Week 22.

    Biological: Upadacitinib · Drug: Placebo to dupilumab

  • Experimental
    Dupilumab 300 mg EOW

    Participants will receive a loading dose of 600 mg dupilumab by subcutaneous (SC) injection on Day 1 followed by 300 mg dupilumab SC every other week (EOW) until Week 22 and placebo to upadacitinib orally QD up to Week 24.

    Biological: Dupilumab · Drug: Placebo to upadacitinib

Interventions

  • BiologicalUpadacitinib

    Extended release tablet

    Also known as: ABT-494, RINVOQ®

  • BiologicalDupilumab

    Dupilumab is administered as a subcutaneous (SC) injection

    Also known as: Dupixent®

  • DrugPlacebo to dupilumab

    Placebo administered as a subcutaneous injection

  • DrugPlacebo to upadacitinib

    Tablet

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

    Time frame: Baseline (Week 0) to Week 16

  2. Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  3. Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 16

  4. Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

    Time frame: Baseline (Week 0) to Week 4

  5. Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2

    EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

    Time frame: Baseline and Week 2

  6. Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

    Time frame: Baseline (Week 0) to Week 1

  7. Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

    The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

    Time frame: Baseline and Week 16

07

Results

Posted Feb 2, 2022

Participant flow

Participants were randomized at 128 sites located in 22 countries (Australia, Canada, Croatia, Czechia, Finland, France, Germany, Hungary, Ireland, Israel, Italy, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Spain, Taiwan, Ukraine, United Kingdom, and the United States).

Participant flow — Overall Study
MilestoneDupilumab 300 mg EOWUpadacitinib 30 mg QD
Started331342
Completed308312
Not completed2330
Withdrew: Adverse event37
Withdrew: Withdrawal by subject811
Withdrew: Lost to follow-up75
Withdrew: Covid-19 logistical restrictions11
Withdrew: Other46

Outcome measures

PrimaryPercentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 16
percentage of participantsDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percentage of Participants Achieving a 75% Reduction From Baseline in Eczema Area and Severity Index Score (EASI 75) at Week 1662.6 (57.4 to 67.8)72.4 (67.6 to 77.2)
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = 0.007 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Adjusted response rate difference: 9.7 · 95% CI 2.6 to 16.7Response rate difference = Upadacitinib - Dupilumab
SecondaryPercent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

Time frame:
Baseline (Week 0) to Week 16
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16
percent changeDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 16-49.58 ± 1.986-67.78 ± 1.906
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Least squares (ls) mean difference: -18.21 · 95% CI -23.61 to -12.80Difference = Upadacitinib - Dupilumab
SecondaryPercentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
percentage of participantsDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 167.9 (5.0 to 10.8)28.4 (23.6 to 33.2)
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Adjusted response rate difference: 20.4 · 95% CI 14.8 to 26.0Response rate difference = Upadacitinib - Dupilumab
SecondaryPercentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
percentage of participantsDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 1640.3 (35.0 to 45.6)61.6 (56.4 to 66.8)
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Adjusted response rate difference: 21.2 · 95% CI 13.8 to 28.6Response rate difference = Upadacitinib - Dupilumab
SecondaryPercent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

Time frame:
Baseline (Week 0) to Week 4
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4
percent changeDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 4-32.39 ± 2.288-60.41 ± 2.204
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Ls mean difference: -28.02 · 95% CI -34.25 to -21.78Difference = Upadacitinib - Dupilumab
SecondaryPercentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2

EASI is a tool used to measure the extent (area) and severity of atopic eczema based on assessments of the head/neck, trunk, upper limbs and lower limbs. For each region the area score is recorded as the percentage of skin affected by eczema. For each region, the severity score is calculated as the sum of the intensity scores (scored as none \[0\], mild \[1\], moderate \[2\], or severe \[3\]) for redness (erythema, inflammation), thickness (induration, papulation, swelling - acute eczema), scratching (excoriation), and lichenification (lined skin, prurigo nodules - chronic eczema). The total EASI score for each region is calculated by multiplying the severity score by the area score, with adjustment for the proportion of the body region to the whole body. The final EASI score is the sum of the 4 region scores and ranges from 0 to 72 where higher scores represent worse disease.

Time frame:
Baseline and Week 2
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 2
percentage of participantsDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percentage of Participants Achieving a 75% Reduction From Baseline in EASI Score at Week 218.2 (14.0 to 22.4)44.3 (39.1 to 49.6)
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Adjusted response rate difference: 26.0 · 95% CI 19.3 to 32.7Response rate difference = Upadacitinib - Dupilumab
SecondaryPercent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch). The percent change from Baseline was calculated from a rolling weekly average; a negative change from Baseline indicates improvement.

Time frame:
Baseline (Week 0) to Week 1
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1
percent changeDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percent Change From Baseline in Worst Pruritus Numerical Rating Scale (NRS) Score at Week 1-8.94 ± 1.831-31.96 ± 1.772
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Mixed Effect Model Repeated Measurement · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Ls mean difference: -23.02 · 95% CI -28.03 to -18.02Difference = Upadacitinib - Dupilumab
SecondaryPercentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16

The Worst Pruritus NRS is an assessment tool that participants used to report the intensity of their pruritus during a 24-hour recall period using an electronic hand-held device. Participants were asked to rate itch (pruritus) intensity at its worst during the past 24 hours on an 11-point scale from 0 (no itch) to 10 (worst imaginable itch).

Time frame:
Baseline and Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 16
percentage of participantsDupilumab 300 mg EOWUpadacitinib 30 mg QD
Percentage of Participants Achieving a Reduction of ≥ 4 Points From Baseline in Worst Pruritus NRS at Week 1636.4 (31.1 to 41.6)56.1 (50.8 to 61.5)
Statistical analysis
  • Dupilumab 300 mg EOW vs Upadacitinib 30 mg QD · Cochran-Mantel-Haenszel · p = <0.001 (A multiple testing procedure was used to provide a strong control of the type I error rate at alpha = 0.05 (2-sided) across analyses comparing upadacitinib versus dupilumab with respect to the primary and ranked secondary endpoints.) · Adjusted response rate difference: 19.8 · 95% CI 12.4 to 27.3Response rate difference = Upadacitinib - Dupilumab

Adverse events

Collected over All-cause mortality was recorded from Day 1 up to 12 weeks after last injection (34 weeks). Treatment-emergent adverse events are from first dose of upadacitinib/dupilumab through 30 days following the last dose of upadacitinib or 84 days following the last dose of dupilumab (up to 34 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dupilumab 300 mg EOW0/331 (0%)7/331 (2.1%)134/331 (40.5%)
Upadacitinib 30 mg QD1/342 (0.3%)14/342 (4.1%)167/342 (48.8%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
EventDupilumab 300 mg EOWUpadacitinib 30 mg QD
INCARCERATED UMBILICAL HERNIAGastrointestinal disorders1/3310/342
TYPE I HYPERSENSITIVITYImmune system disorders1/3310/342
CELLULITISInfections and infestations1/3310/342
ERYSIPELASInfections and infestations1/3310/342
PELVIC FRACTUREInjury, poisoning and procedural complications1/3310/342
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations1/3310/342
BURSITISMusculoskeletal and connective tissue disorders1/3310/342
ASTHMARespiratory, thoracic and mediastinal disorders1/3310/342
LYMPHOPENIABlood and lymphatic system disorders0/3311/342
NEUTROPENIABlood and lymphatic system disorders0/3311/342
Most frequent other events
Most frequent other events
EventDupilumab 300 mg EOWUpadacitinib 30 mg QD
ACNESkin and subcutaneous tissue disorders11/33164/342
CONJUNCTIVITISInfections and infestations35/3315/342
DERMATITIS ATOPICSkin and subcutaneous tissue disorders32/33136/342
NASOPHARYNGITISInfections and infestations27/33123/342
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations17/33126/342
BLOOD CREATINE PHOSPHOKINASE INCREASEDInvestigations10/33126/342
HEADACHENervous system disorders24/33117/342
FOLLICULITISInfections and infestations4/33122/342
URINARY TRACT INFECTIONInfections and infestations15/33118/342
ORAL HERPESInfections and infestations9/33117/342

Baseline characteristics

The intent-to-treat (ITT) population includes all randomized participants according to the treatment groups that they were randomized to.

Age, Continuous
Age, Continuous(years)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
Mean36.3 ± 13.8136.2 ± 14.4236.3 ± 14.11
Age, Customized
Age, Customized(Participants)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
< 40 years223228451
≥ 40 to < 65 years9498192
≥ 65 years141630
Sex: Female, Male
Sex: Female, Male(Participants)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
Female139159298
Male192183375
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
Hispanic or Latino312556
Not Hispanic or Latino300317617
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
White231229460
Black or African American152540
Asian7877155
American Indian/Alaska Native123
Native Hawaiian or Other Pacific Islander134
Multiple5611
Disease Severity
Disease Severity(Participants)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
3 (Moderate)159169328
4 (Severe)172173345
Eczema Area and Severity Index (EASI) Score
Eczema Area and Severity Index (EASI) Score(score on a scale)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
Mean29.21 ± 11.55130.96 ± 12.55030.10 ± 12.092
Duration Since AD Diagnosis
Duration Since AD Diagnosis(years)Dupilumab 300 mg EOWUpadacitinib 30 mg QDTotal
Mean25.474 ± 14.825123.608 ± 14.769724.526 ± 14.8154
08

Study locations

159 sites
  • Clinical Research Center AL /ID# 210277
    Birmingham, Alabama 35209-6802, United States
  • University of Arkansas for Medical Sciences /ID# 211688
    Little Rock, Arkansas 72205, United States
  • Tien Q Nguyen MD, Inc /ID# 208934
    Fountain Valley, California 92708-3701, United States
  • UCSF Fresno /ID# 213253
    Fresno, California 93701-2302, United States
  • Jonathan Corren, MD. INC /ID# 208987
    Los Angeles, California 90025-4749, United States
  • California Allergy and Asthma Medical Group /ID# 213680
    Los Angeles, California 90025-7014, United States
  • Dermatology Research Associates /ID# 209097
    Los Angeles, California 90045, United States
  • Los Angelos Cataract Center /ID# 208524
    Los Angeles, California 90056, United States
  • Dermatology Clinical Trials /ID# 214622
    Newport Beach, California 92660-7853, United States
  • UC Davis Health /ID# 209285
    Sacramento, California 95816, United States
  • Ucsd /Id# 208990
    San Diego, California 92103, United States
  • Clinical Science Institute /ID# 211022
    Santa Monica, California 90404-2102, United States
  • The Community Research of South Florida /ID# 211145
    Hialeah, Florida 33016-1897, United States
  • Miami Dermatology and Laser Institute /ID# 212938
    Miami, Florida 33173-3570, United States
  • Florida International Rsrch cr /ID# 211562
    Miami, Florida 33173, United States
  • Progressive Medical Research /ID# 211994
    Port Orange, Florida 32127, United States
  • GCP Research /ID# 216020
    Saint Petersburg, Florida 33705, United States
  • Clinical Research Trials of Florida, Inc. /ID# 210751
    Tampa, Florida 33607, United States
  • Integrated Clinical Research LLC /ID# 208831
    West Palm Beach, Florida 33406-6063, United States
  • Georgia Pollens Clinical Research Centers, Inc /ID# 211092
    Albany, Georgia 31707-1282, United States
  • Meridian Clinical Research Dermatology /ID# 213251
    Savannah, Georgia 31406-2632, United States
  • Northwestern University Feinberg School of Medicine /ID# 208680
    Chicago, Illinois 60611-2927, United States
  • Medical Dermatology Associates of Chicago /ID# 210265
    Chicago, Illinois 60654-6903, United States
  • Sneeze, Wheeze, & Itch Associates, LLC /ID# 212058
    Normal, Illinois 61761, United States
  • Dawes Fretzin, LLC /ID# 209187
    Indianapolis, Indiana 46256, United States
  • Beacon Clinical Research, LLC /ID# 209280
    Quincy, Massachusetts 02169, United States
  • Clarkston Skin Research /ID# 208739
    Clarkston, Michigan 48346, United States
  • Henry Ford Health System /ID# 208741
    Detroit, Michigan 48202, United States
  • Clinical Research Institute, Inc /ID# 210852
    Minneapolis, Minnesota 55402-2606, United States
  • Allergy, Asthma & Immunology Associates, PC /ID# 213481
    Lincoln, Nebraska 68505-2343, United States
  • Skin Specialists, PC /ID# 208843
    Omaha, Nebraska 68144, United States
  • Dartmouth-Hitchcock Medical Center /ID# 213727
    Lebanon, New Hampshire 03756, United States
  • Montefiore Medical Center /ID# 209647
    Bronx, New York 10467, United States
  • Forest Hills Dermatology Group /ID# 209249
    Kew Gardens, New York 11415, United States
  • Wake Forest Univ HS /ID# 208892
    Winston-Salem, North Carolina 27157, United States
  • Univ Hosp Cleveland /ID# 208852
    Cleveland, Ohio 44106, United States
  • The Ohio State University /ID# 209254
    Columbus, Ohio 43210-1257, United States
  • Southside Dermatology /ID# 212004
    Tulsa, Oklahoma 74132, United States
  • Oregon Medical Res Center PC /ID# 208807
    Portland, Oregon 97223, United States
  • Oregon Health and Science University /ID# 208809
    Portland, Oregon 97239, United States
  • Medical University of South Carolina /ID# 211054
    Charleston, South Carolina 29425, United States
  • Clinical Research Solutions, LLC /ID# 212542
    Jackson, Tennessee 38305-2163, United States
  • Orion Clinical Research /ID# 208765
    Austin, Texas 78759-4100, United States
  • DiscoveResearch, Inc. /ID# 213171
    Bryan, Texas 77802, United States
  • Epiphany Dermatology - Fort Worth /ID# 211187
    Fort Worth, Texas 76244-6548, United States
  • Sante Clinical Research /ID# 212970
    Kerrville, Texas 78028-9640, United States
  • Stephen Miller, MD PA /ID# 210071
    San Antonio, Texas 78249, United States
  • Sugar Land Allergy, Asthma, and Immunology Center /ID# 211153
    Sugar Land, Texas 77479-3153, United States
  • University of Utah /ID# 209001
    Salt Lake City, Utah 84112-5500, United States
  • Clinical Research Partners, LLC /ID# 212262
    Richmond, Virginia 23220-4459, United States
  • Premier Clinical Research /ID# 212142
    Spokane, Washington 99202, United States
  • West Virginia Research Inst /ID# 212730
    South Charleston, West Virginia 25309, United States
  • Holdsworth House Medical Practice /ID# 214565
    Darlinghurst, New South Wales 2010, Australia
  • The Skin Hospital /ID# 214401
    Darlinghurst, New South Wales 2010, Australia
  • Veracity Clinical Research /ID# 211134
    Woolloongabba, Queensland 4102, Australia
  • Sinclair Dermatology /ID# 209395
    East Melbourne, Victoria 3002, Australia
  • Burswood Dermatology /ID# 214875
    Victoria Park, Western Australia 6100, Australia
  • Kirk Barber Research, CA /ID# 209504
    Calgary, Alberta T2G 1B1, Canada
  • Dermatology Research Institute Inc. /ID# 210942
    Calgary, Alberta T2J 7E1, Canada
  • Dr. Chih-ho Hong Medical Inc. /ID# 211032
    Surrey, British Columbia V3R 6A7, Canada
  • Enverus Medical Research /ID# 209503
    Surrey, British Columbia V3V 0C6, Canada
  • Dr. Wei Jing Loo Medicine Prof /ID# 211400
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc. /ID# 209505
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research Inc. /ID# 211122
    Mississauga, Ontario L5H 1G9, Canada
  • Niakosari Medicine Professional Corporation /ID# 211401
    Toronto, Ontario M2M 4J5, Canada
  • K. Papp Clinical Research /ID# 209509
    Waterloo, Ontario N2J 1C4, Canada
  • Dre Angelique Gagne-Henley M.D. inc. /ID# 209498
    Saint-Jerome, Quebec J7Z 7E2, Canada
  • DermaPlus - Poliklinika za dermatologiju i venerologiju /ID# 209935
    Zagreb, Grad Zagreb 10000, Croatia
  • Djecja bolnica Srebrnjak /ID# 209939
    Zagreb, Grad Zagreb 10000, Croatia
  • Klinicki bolnicki centar Zagreb /ID# 209976
    Zagreb, Grad Zagreb 10000, Croatia
  • Naftalan - Specijalna bolnica za medicinsku rehabilitaciju /ID# 209937
    Ivanic-Grad, Zagrebacka Zupanija 10310, Croatia
  • Fakultni Nemocnice Brno /ID# 212968
    Brno, 625 00, Czechia
  • FN Hradec Kralove /ID# 209116
    Hradec Kralove, 500 05, Czechia
  • Nemocnice Jihlava, prispevkova organizace /ID# 209131
    Jihlava, 586 01, Czechia
  • Fakultni nemocnice Ostrava /ID# 209117
    Ostrava, 708 52, Czechia
  • Fakultni Nemocnice v Motole /ID# 209209
    Praha, 150 06, Czechia
  • Keski-pohjanmaa Central Hospital /ID# 209534
    Kokkola, Keski-Pohjanmaa 67200, Finland
  • Oulu University Hospital /ID# 208961
    Oulu, Pohjois-Pohjanmaa 90220, Finland
  • Mikkeli Central Hospital /ID# 210125
    Mikkeli, 50100, Finland
  • Pihlajalinna Turku /ID# 209599
    Turku, 20100, Finland
  • CHRU Lille - Hopital Claude Huriez /ID# 209317
    Lille CEDEX, Hauts-de-France 59045, France
  • CHU de Nantes - Hotel Dieu /ID# 208974
    Nantes CEDEX 1, Pays-de-la-Loire 44093, France
  • Charles Nicolle CHU Rouen /ID# 208973
    Rouen CEDEX, Seine-Maritime 76031, France
  • Hopital de la Timone /ID# 211245
    Marseille, 13385, France
  • Centre Hospitalier Universitaire de Nice - Hopital l'Archet 2 /ID# 213374
    Nice, 06202, France
  • Polyclinique Courlancy /ID# 208975
    Reims, 51100, France
  • Hopital Larrey - CHU de Toulouse /ID# 208976
    Toulouse, 31059, France
  • Universitatsklinikum Munster /ID# 210935
    Munster, Niedersachsen 48149, Germany
  • Gemeinschaftspraxis /ID# 211174
    Blankenfeld-mahlow, 15831, Germany
  • Hautklinik Klinikum Darmstadt /ID# 210938
    Darmstadt, 64283, Germany
  • Universitaetsklinikum Frankfurt /ID# 210934
    Frankfurt, 60590, Germany
  • Medizinische Hochschule Hannover /ID# 210939
    Hannover, 30625, Germany
  • TU Uniklinik Munchen /ID# 210937
    Munich, 80802, Germany
  • Oroshazi Korhaz /ID# 210150
    Oroshaza, Bekes 5900, Hungary
  • Uno Medical Trials Kft /ID# 211177
    Budapest XIII, 1135, Hungary
  • Debreceni Egyetem Klinikai Kozpont /ID# 210893
    Debrecen, 4032, Hungary
  • Somogy Megyei Kaposi Mor Oktat /ID# 210149
    Kaposvar, 7400, Hungary
  • Pecsi Tudomanyegyetem Klinikai l.sz. Belgyogyaszati Klinika /ID# 210892
    Pecs, 7624, Hungary
  • St Vincent's University Hosp /ID# 208441
    Dublin, D04 T6F4, Ireland
  • University Hospital Waterford /ID# 208442
    Waterford, X91 ER8E, Ireland

Showing the first 100 of 159 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Blauvelt A, Teixeira HD, Simpson EL, Costanzo A, De Bruin-Weller M, Barbarot S, Prajapati VH, Lio P, Hu X, Wu T, Liu J, Ladizinski B, Chu AD, Eyerich K. Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2021 Sep 1;157(9):1047-1055. doi: 10.1001/jamadermatol.2021.3023. Erratum In: JAMA Dermatol. 2022 Feb 1;158(2):219. doi: 10.1001/jamadermatol.2021.5451. JAMA Dermatol. 2022 Feb 1;158(2):219. doi: 10.1001/jamadermatol.2022.0056. JAMA Dermatol. 2024 Mar 1;160(3):370. doi: 10.1001/jamadermatol.2023.6395. JAMA Dermatol. 2024 Sep 1;160(9):1012. doi: 10.1001/jamadermatol.2024.2673. PubMed 34347860 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Use Agreement (DUA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Aug 2020, 18 months.

Results were first posted in Feb 2022, 1 year 5 months after primary completion. A results delay was requested in Jul 2021.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 18 months is close to that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2018
First posted
Nov 13, 2018
StartActual
Feb 21, 2019
Primary completionActual
Aug 27, 2020
CompletionActual
Dec 9, 2020
Results delay requested
Jul 1, 2021
Results first posted
Feb 2, 2022
Last update
Mar 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03738397
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Nov 13, 2018
Start date
Feb 21, 2019
Primary completion
Aug 27, 2020
Completion
Dec 9, 2020
Results posted
Feb 2, 2022
Last update
Mar 15, 2024

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Upadacitinib

Start the discussion